GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK3923868
Drug: Placebo

First Posted Date: 2023-01-10

Last Posted Date: 2024-10-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT05677347

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

Phase 1

Recruiting

Conditions: Anaemia, Sickle Cell
Hematologic Diseases

Interventions: Drug: GSK4172239D
Other: Placebo

First Posted Date: 2022-12-21

Last Posted Date: 2025-04-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT05660265

Locations: 🇺🇸
GSK Investigational Site, Raleigh, North Carolina, United States

A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India

Phase 4

Completed

Conditions: Influenza, Human

Interventions: Biological: Fluarix Tetra Vaccine

First Posted Date: 2022-12-13

Last Posted Date: 2025-03-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 250

Registration Number: NCT05648357

Locations: 🇮🇳
GSK Investigational Site, Vishakha Patnam, India

A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)

Phase 3

Completed

Conditions: Urinary Tract Infections

Interventions: Drug: Gepotidacin
Drug: Nitrofurantoin
Drug: Placebo

First Posted Date: 2022-11-30

Last Posted Date: 2025-03-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 380

Registration Number: NCT05630833

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

Phase 3

Active, not recruiting

Conditions: Chronic Hepatitis B
Hepatitis B, Chronic

Interventions: Other: Placebo
Drug: Bepirovirsen

First Posted Date: 2022-11-30

Last Posted Date: 2025-04-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 981

Registration Number: NCT05630807

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.

Phase 1

Active, not recruiting

Conditions: Sexually Transmitted Diseases

Interventions: Biological: Placebo
Biological: NgG medium dose investigational vaccine
Biological: NgG high dose investigational vaccine
Biological: NgG below HTD investigational vaccine
Biological: NgG low dose investigational vaccine
Biological: NgG HTD investigational vaccine

First Posted Date: 2022-11-30

Last Posted Date: 2024-04-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1004

Registration Number: NCT05630859

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Phase 2

Completed

Conditions: Measles; Mumps; Rubella; Chickenpox
Measles

Interventions: Biological: Investigational MMRV(H)NS vaccine
Biological: Marketed MMRV_Lot 1 and Lot 2 vaccine
Biological: Investigational MM(H)RVNS vaccine
Biological: Investigational M(L)M(L)R(L)V(L)NS vaccine

First Posted Date: 2022-11-30

Last Posted Date: 2025-02-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 801

Registration Number: NCT05630846

Locations: 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

Phase 3

Active, not recruiting

Conditions: Chronic Hepatitis B
Hepatitis B, Chronic

Interventions: Other: Placebo
Drug: Bepirovirsen

First Posted Date: 2022-11-30

Last Posted Date: 2024-08-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 871

Registration Number: NCT05630820

Locations: 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom

Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

Phase 1

Completed

Conditions: Typhoid Fever

Interventions: Biological: TYP04A Low Dose without Alum investigational vaccine
Biological: TYP04B Full Dose without Alum investigational vaccine
Biological: TYP03A Low Dose with Alum investigational vaccine
Biological: Sanofi Pasteur's Typhoid Vi polysaccharide vaccine
Biological: TYP03B Full Dose with Alum investigational vaccine
Biological: TYP03A Low Dose adjuvanted investigational vaccine
Biological: TYP03B Full Dose adjuvanted investigational vaccine
Biological: TYP04A Low Dose without adjuvant investigational vaccine
Biological: TYP04B Full Dose without adjuvant investigational vaccine
Biological: GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine